Hepatic Issues and Complications Associated With Inflammatory Bowel Disease

Saubermann, Lawrence J.; Deneau, Mark; Falcone, Richard A.; Murray, Karen F.; Ali, Sabina; Kohli, Rohit; Ekong, Udeme D.; Valentino, Pamela L.; Grossman, Andrew B.; Rand, Elizabeth B.; Jonas, Maureen M.; Saeed, Shehzad Ahmed; Kamath, Binita M.

doi:10.1097/mpg.0000000000001492

Cited by 28 publications

(30 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, immunosuppression can lead to a reactivation of hepatitis B 101 or cause hepatitis mediated by other viruses, such as cytomegalovirus, Epstein-Barr virus, and others. [102][103][104][105] The prevalence of true hepatic EIMs is reported to be low (<1%). The discrimination from treatment adverse effects usually is difficult.…”

Section: Hepatobiliary Extraintestinal Manifestations In Inflammatory Bowel Diseasementioning

confidence: 99%

Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are systemic diseases that manifest not only in the gut and gastrointestinal tract, but also in the extraintestinal organs in many patients. The quality of life for patients with IBD can be substantially affected by these extraintestinal manifestations (EIMs). It is important to have knowledge of the prevalence, pathophysiology, and clinical presentation of EIMs in order to adapt therapeutic options to cover all aspects of IBD. EIMs can occur in up to 24% of patients with IBD before the onset of intestinal symptoms, and need to be recognized to initiate appropriate diagnostic procedures. EIMs most frequently affect joints, skin, or eyes, but can also affect other organs, such as the liver, lung, and pancreas. It is a frequent misconception that a successful therapy of the intestinal inflammation will be sufficient to treat EIMs satisfactorily in most patients with IBD. In general, peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum can be associated with active intestinal inflammation and can improve on standard treatment of the intestinal inflammation. However, anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis usually occur independent of disease flares. This review provides a comprehensive overview of epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in IBD.

show abstract

Section: Hepatobiliary Extraintestinal Manifestations In Inflammatory Bowel Diseasementioning

confidence: 99%

Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, there is a lack of studies assessing the effects of such treatment in children. According to recommendations, all children infected with HCV who receive anti-TNF agents should have regular evaluation of liver enzymes and viral copies (HCV RNA) [39].…”

Section: Viral Hepatitismentioning

confidence: 99%

Hepatobiliary manifestations of inflammatory bowel disease in children

Kucharska¹,

Daniluk²,

Kwiatek-Sredzinska³

et al. 2019

ceh

View full text Add to dashboard Cite

show abstract

“…In a population‐based study, PSC‐AIH overlap was identified in 1.5% of children with IBD, 2.3% in patients with UC, and 0.9% in patients with CD 12 . Elevations in transaminases can occur after an IBD exacerbation, and progression of the biliary disease may be associated with intestinal inflammation 13 . Although PSC‐AIH can respond to the same therapies used in AIH, the prognosis tends to be worse because of progression of biliary disease.…”

Section: Pscmentioning

confidence: 99%